select search filters
briefings
roundups & rapid reactions
factsheets & briefing notes
before the headlines
Fiona fox's blog

Tag search results

neuraminidase inhibitors in influenza

Pandemic influenza tops the UK’s National Risk Register due to the social and economic disruption that could result from a particularly virulent strain. Questions have been raised for some years about the efficacy and effectiveness of neuraminidase inhibitors (NAIs)Tamiflu and Relenza, the principal antiviral drugs used in treating flu, and whether this justifies their being part of the UK government’s response to influenza. In response to a request from the UK Department of Health, a small, independent steering group was established by the Academy of Medical Sciences and the Wellcome Trust to review the recent evidence about the use of NAIs, consider the pipeline for new treatments for influenza, and identify research priorities. read more

gain-of-function flu research – what is it for?

We’ve heard about lab experiments on influenza that mutate the virus to investigate how genetic changes could alter how infectious or deadly it is. But what are these gain-of-function experiments, how and where are they conducted, and what have we learned from them so far? read more

Tamiflu and Relenza for treatment and prevention of influenza

The Cochrane Collaboration published an evidence review of Tamiflu (the antiviral drug oseltamivir) and Relenza (zanamivir) trials, reporting that Tamiflu shortens symptoms of influenza but other claims made for the drugs were not well supported by evidence from clinical study reports. read more

new study on effectiveness of Tamiflu and Relenza

Authors of the latest updated ‘Cochrane Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children’ came came to the SMC to outline their findings about the effectiveness of Tamilflu and Relenza. read more

Show More
Show 100 More

{this may take a while}

search by tag

see the latest